SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group is trending due to strong community reactions surrounding Donald Trump's recent policy discussions, including controversial tariff proposals, and renewed conversation around alleged withheld Epstein files, fueling a highly polarized debate on his public statements and their broader economic implications.

Zeta Global Holdings Corp. operates as a marketing technology software company, which engages in the provision of enterprises with consumer intelligence and marketing automation software. It enables its customers to target, connect and engage consumers through software that delivers marketing across all addressable channels, including email, social media, web chat, connected TV and video among others. The company was founded by David A. Steinberg and John Sculley on May 9, 2012 and is headquartered in New York, NY.

Zeta Global Holdings Corp - Ordinary Shares - Class A

Zeta Global Holdings Corp

Zeta Global Holdings Corp is trending after an earnings report that showcased continued strong performance, including reaching GAAP profitability and reiterating its role as an AI disruptor, which is fueling community excitement and a reevaluation of the stock despite challenges facing the broader software sector.

FuelCell Energy, Inc. engages in the business of developing, designing, producing, constructing, and servicing high temperature fuel cells for clean electric power generation. It operates through the following geographical segments: the United States, South Korea, and Europe. The company was founded by Bernard Baker and Martin G. Klein in 1969 and is headquartered in Danbury, CT.

Fuelcell Energy Inc

Fuelcell Energy is trending due to renewed optimism for its fuel cell and carbon capture technology, positioned to meet the surging power demands of AI data centers following a significant strategic collaboration. The community is actively debating its potential for major contract wins against a backdrop of historical dilution concerns and calls for concrete execution from management.

Anterix, Inc. engages in commercializing spectrum assets to enable targeted utility and critical infrastructure customers to deploy private broadband networks, technologies and solutions. Its solutions include Private LTE and Active Ecosystem. The company was founded by Peter Joel Lasensky and Richard Edward Rohmann in 1997 and is headquartered in Woodland Park, NJ.

Anterix Inc

Anterix is trending as the community widely believes its scarce nationwide 900 MHz spectrum is massively undervalued following a significant FCC regulatory expansion enabling full 5G LTE broadband deployment. Investors are actively pointing to a substantial discount compared to market benchmarks and ongoing strategic review efforts, anticipating future contract announcements that could drive a significant re-rating given its strategic position in utility grid modernization.

Cava Group, Inc. is a holding company, which engages in the category-defining Mediterranean fast-casual restaurant brand, bringing together healthful food and bold, satisfying flavors at scale. It operates through the following segments: CAVA and CAVA Foods. The CAVA segment includes the operations of all company-owned CAVA restaurants. The CAVA Foods segment includes the production of dips and spreads used in CAVA restaurants as well as sales from the consumer-packaged goods (CPG) business. The company was founded by Brett Schulman, Ike Grigoropoulus, Dimitri Moshovitis, and Theodore Xenohristos in 2010 and is headquartered in Washington, DC.

Cava Group Inc

CAVA Group Inc

CAVA is rallying following its Q4 earnings, which showed revenue growth and strong restaurant expansion, although community discussion is split over its high valuation, tempered same-store sales growth, and comparisons to Chipotle's financial metrics.

Axon Enterprise, Inc. engages in the development, manufacture, and sale of conducted electrical weapons for personal defense. It operates through the TASER segment and Software and Sensors segment. The TASER segment sells conducted electrical weapons, accessories, and other related products and services. The Software and Sensors segment includes devices, wearables, applications, cloud, and mobile products. The company was founded by Patrick W. Smith and Thomas P. Smith on September 7, 1993 and is headquartered in Scottsdale, AZ.

Axon Enterprise Inc

Axon Enterprise is trending following a significant earnings beat and strong forward guidance, with the community celebrating its robust performance and discussing potential short squeezes. Investors are highlighting its profitable compounding and defensible position as an integrated hardware and software public safety technology leader, distinguishing it from broader software market fatigue.

First Solar, Inc. is a solar technology company, which engages in the provision of solar modules. It is involved in the design, manufacture, and sale of cadmium tellurid (CdTe) solar modules, which convert sunlight into electricity. The company was founded by Michael J. Ahearn in 1999 and is headquartered in Tempe, AZ.

First Solar Inc

First Solar is trending following its recent earnings report, which included 2026 sales guidance falling below analyst expectations, leading to a notable sell-off. The community is divided, with some viewing the dip as an overreaction and a buying opportunity, while others anticipate further declines due to concerns over tariffs and broader policy uncertainty impacting future growth.

SSgA Active Trust - State Street SPDR S&P 500 ETF Trust

SPY is trending due to widespread community discussion surrounding recent political rhetoric from a State of the Union speech, focusing on its economic claims and the resulting polarization, while also anticipating key NVIDIA earnings for broader market direction.

BlockDAG

BlockDAG is trending due to widespread community frustration over technical issues preventing users from claiming their presale tokens and connecting wallets, leading to intense debate and accusations of it being a scam amidst conflicting information about its exchange listings and vesting schedules.

NIO, Inc. is a holding company which engages in the design, manufacture, and sale of electric vehicles. Its products include the EP9 supercar and ES8 7-seater SUV. It provides users with home charging, power express valet services, and other power solutions including access to public charging, access to power mobile charging trucks, and battery swapping. It also offers other value-added services such as service package, battery payment arrangement, and vehicle financing and license plate registration. The company was founded by Bin Li and Li Hong Qin on November 28, 2014 and is headquartered in Jiading, China.

NIO Inc - ADR

NIO Inc

NIO is trending due to record-breaking battery swap milestones, including surpassing 100 million total swaps and new daily highs, which is intensifying community debate around its unique business model, future profitability, and stock price movements often linked to claims of market manipulation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>The company's Q4 revenue rose to $202.1 million, but net income fell to $24.3 million.</li><li>Corcept said demand for its Cushing syndrome business surged in 2025, with record prescriptions and prescribers.</li><li>Corcept pushed back on the FDA’s decision to reject Relacorilant in December, saying that an April FDA meeting will be critical to determining next steps.</li></ul>Shares of Corcept Therapeutics, Inc. (CORT) slipped in extended trading on Tuesday after weaker-than-expected fourth-quarter (Q4) profit, as investors weighed the setback to its Cushing syndrome drug ahead of a key FDA meeting in April.<a href="https://stocktwits.com/symbol/CORT">CORT stock</a> jumped over 3% in Tuesday’s regular session.<h2 class="st-heading-2">CORT Q4 Results And 2026 Outlook</h2>Corcept reported Q4 revenue of $202.1 million, up from $181.9 million a year earlier but below expectations, while net income fell to $24.3 million, or $0.2 per diluted share, from $30.7 million, or $0.26 per share, also missing estimates.For the full year, revenue rose to $761.4 million from $675.0 million in 2024, while net income declined to $99.7 million from $141.2 million. Corcept guided for full-year 2026 revenue of $900 million to $1 billion.&nbsp;“In 2025, our Cushing’s syndrome business experienced a surge in demand due to growing recognition among physicians of hypercortisolism’s true prevalence and the necessity of appropriate treatment,” CEO Joseph K. Belanoff said, adding that there was a record number of new prescriptions and prescribers.However, Belanoff noted that growth was partially constrained by capacity issues and operational disruptions tied to a specialty pharmacy transition in Q4. He said the transition is now complete, and February is on track to be a record month for new patient starts.<h2 class="st-heading-2">FDA Rejection Keeps Focus On Relacorilant</h2>Investor attention remains centered on Relacorilant after the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter in December, refusing approval of the drug for patients with hypercortisolism, also known as Cushing syndrome.In an&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/cort-shares-plummer-on-fda-drug-rejection-letter-reveal/cmySqTUR4SV">amended letter</a> published last month, the FDA said the late-stage trial results were insufficient to demonstrate effectiveness and flagged concerns around drug-induced liver injury. The agency also said it had raised concerns during pre-submission meetings about the adequacy of Corcept’s clinical development program, particularly regarding the assessment of effects on hypertension, and requested new clinical data and risk mitigation strategies.While the FDA acknowledged that Corcept’s pivotal Grace trial met its primary endpoint and that confirmatory evidence was provided, it said it could not reach a “favorable benefit-risk assessment” without additional evidence in December.<h2 class="st-heading-2">Corcept Pushes Back On FDA Decision</h2>On Tuesday’s earnings call, Corcept pushed back on the FDA’s conclusions and said an April FDA meeting will be critical to understanding the decision.Gary Robb, the company’s chief business officer, said Corcept believes the data “clearly met the hurdle for approval” and were consistent with those supporting previously approved treatments. “The confirmatory evidence we provided also met its endpoint until the agency mentioned sort of an analysis at the end that they performed that we had never seen and really can't replicate,” he added.&nbsp;“There is daylight between our position and their position,” Robb said, adding that the April meeting is intended to clarify the FDA’s thinking and determine next steps.Belanoff cited results from the company’s Catalyst study showing that treating hypercortisolism in certain patients led to symptom improvement. He said it is too early to say whether Corcept will pursue a new randomized trial.<h2 class="st-heading-2">Pipeline Beyond Cushing Syndrome</h2>Separately, Corcept said its New Drug Application for Relacorilant in platinum-resistant ovarian cancer remains under FDA review, with a July 11 deadline for the FDA to decide whether to approve the drug, and a European decision expected later this year.&nbsp;The company also outlined multiple ongoing and planned studies across oncology, metabolic disease and (a<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.google.com/search?q=Amyotrophic+Lateral+Sclerosis&amp;sca_esv=82030d20fc0d5849&amp;sxsrf=ANbL-n6CsXNcCbD0Jf2HDjdwkbZaPdUv9g%3A1772002173901&amp;ei=fZueaaXPNuOo4-EPjc7WmAQ&amp;biw=1920&amp;bih=911&amp;ved=2ahUKEwj-udm2h_SSAxX1xjgGHc8qLfQQgK4QegYIAAgAEAQ&amp;uact=5&amp;oq=als+full+form%5C&amp;gs_lp=Egxnd3Mtd2l6LXNlcnAiDmFscyBmdWxsIGZvcm1cMggQABiABBixAzIFEAAYgAQyBRAAGIAEMgUQABiABDIFEAAYgAQyBRAAGIAEMgUQABiABDIFEAAYgAQyBRAAGIAEMgUQABiABEi8D1AAWLkPcAB4AJABAJgB3AGgAbgTqgEFMC45LjS4AQPIAQD4AQGYAg2gAv8TwgIKEC4YgAQYQxiKBcICERAuGIAEGJECGNEDGMcBGIoFwgIREC4YgAQYsQMY0QMYgwEYxwHCAgUQLhiABMICCxAuGIAEGNEDGMcBwgILEAAYgAQYsQMYgwHCAhkQLhiABBhDGIoFGJcFGNwEGN4EGN8E2AEBwgILEAAYgAQYkQIYigXCAhEQLhiABBiRAhjHARiKBRivAcICCBAuGIAEGLEDwgIOEC4YgAQYsQMY0QMYxwHCAg0QABiABBixAxhDGIoFmAMAugYGCAEQARgUkgcFMC43LjagB6GRAbIHBTAuNy42uAf_E8IHBzAuNC44LjHIBzWACAA&amp;sclient=gws-wiz-serp">myotrophic lateral sclerosis</a>) ALS, including a planned Phase 3 trial of Dazucorilant in ALS by mid-year.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment for CORT was ‘bullish’ amid a 1,200% surge in 24-hour&nbsp; message volume.<figure class="image"><img src="https://news.stocktwits-cdn.com/cort_ss_png_60f385c217.webp" alt="cort ss.png" width="966" height="140"><figcaption>CORT sentiment and message volume as of February 25 | Source: Stocktwits</figcaption></figure>One user said, “CORT is a solid, growing company with multiple self-funded catalysts span across endocrinology and oncology. The current SP is an once-in-life-time bargain. GLTA! “<stembedurl>https://stocktwits.com/gucag006/message/645809500</stembedurl>Another user said, “Beaten down and an absolute steal at these prices. This company is going nowhere, buy and hold.”<stembedurl>https://stocktwits.com/The_Scientist/message/645785513</stembedurl>CORT stock has risen 5% year to date.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Corcept Therapeutics logo is seen displayed on the screen of a tablet

CORT Stock Slips After-Hours On Weak Q4 Print: Retail Is Watching April FDA Meeting For Relacorilant As Next Catalyst 

The company guided for $900 million to $1 billion in 2026 revenue.

Equity

Corcept Therapeutics Q4 Earnings Call Highlights

Corcept Therapeutics (NASDAQ:CORT) reported higher revenue in 2025 and issued 2026 guidance as executives used the company's fourth-quarter earnings call to address two major setbacks: an adverse...

CORT Investors Have Opportunity to Lead Corcept Therapeutics Incorporated Securities Fraud Lawsuit with the Schall Law Firm

The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Corcept Therapeutics Incorporated (Corcept or the Company) (NASDAQ: CORT) for...

Corcept Therapeutics (CORT) Q4 Earnings and Revenues Miss Estimates

Corcept (CORT) delivered earnings and revenue surprises of -24.53% and -20.54%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

CORT Stockholder Notice: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Class Action Lawsuit Against Corcept Therapeutics Inc.

CORT Stockholder Notice: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Class Action Lawsuit Against Corcept Therapeutics Inc. CORT Stockholder Notice: Shareholder Rights Law Firm...

Corcept Therapeutics (NASDAQ:CORT) Announces Earnings Results, Misses Estimates By $0.07 EPS

Corcept Therapeutics (NASDAQ:CORT - Get Free Report) posted its earnings results on Tuesday. The biotechnology company reported $0.20 EPS for the quarter, missing analysts' consensus estimates of...

Corcept Therapeutics Announces Fourth Quarter and Full-Year 2025 Audited Financial Results, Provides Corporate Update

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and...

INVESTOR DEADLINE: Corcept Therapeutics Incorporated Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit, Robbins Geller Rudman & Dowd LLP Announces

The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Corcept Therapeutics Incorporated (NASDAQ: CORT) common stock between October 31, 2024 and December 30...

Corcept Therapeutics (CORT) Litigation: Hagens Berman Alerts Corcept (CORT) Investors to Securities Class Action and April 21 Lead Plaintiff Deadline

Corcept Therapeutics (CORT) Litigation: Hagens Berman Alerts Corcept (CORT) Investors to Securities Class Action and April 21 Lead Plaintiff Deadline Corcept Therapeutics (CORT) Litigation: Hagens...

CORT Investors Have Opportunity to Lead Corcept Therapeutics Incorporated Securities Fraud Lawsuit

CORT Investors Have Opportunity to Lead Corcept Therapeutics Incorporated Securities Fraud Lawsuit CORT Investors Have Opportunity to Lead Corcept Therapeutics Incorporated Securities Fraud Lawsuit...

$CORT Q4 &#39;25 Earnings Results &amp; Recap

• Reported GAAP EPS of $0.23 down -20.69% YoY
• Reported revenue of $202.12M up 11.12% YoY
• Corcept Therapeutics Inc expects higher R&amp;D and SG&amp;A expenses in 2026 as clinical programs advance. The Inflation Reduction Act is also anticipated to limit Medicare revenue and reduce Corcept&#39;s profits in 2026 and beyond.

Stocktwits

Corcept Therapeutics Inc

 Q4 '25 Earnings Results & Recap

• Reported GAAP EPS of $0.23 down -20.69% YoY
• Reported revenue of $202.12M up 11.12% YoY
• Corcept Therapeutics Inc expects higher R&D and SG&A expenses in 2026 as clinical programs advance. The Inflation Reduction Act is also anticipated to limit Medicare revenue and reduce Corcept's profits in 2026 and beyond.

This account has been verified as an official STOCKTWITS representative.

Verified Account

Stocktwits Earnings

Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the business of discovering and developing pharmaceutical products and medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol. The company was founded by David B. Singer and Joseph K. Belanoff on May 13, 1998 and is headquartered in Redwood City, CA.

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

Ahead of earnings, sentiment is split between blowout AI growth and concerns around macro pressure, positioning, and post-ER volatility. How do you see it playing out?

CORT
Corcept Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Earnings Recap

Latest CORT News

CORTCorcept Therapeutics Inc